FindTrial
Sign In

Adalimumab in Adult Japanese Subjects With Moderate to Severe Chronic Plaque Psoriasis

Adalimumab in Adult Japanese Subjects With Moderate to Severe Chronic Plaque Psoriasis

Status
Unknown
Phases
Phase 3
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080220270
Enrollment
Unknown
Registered
2006-07-07
Start date
2006-07-07
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Psoriasis

Interventions

investigational material(s) Generic name etc : adalimumab INN of investigational material : adalimumab Therapeutic category code : 399 Agents affecting metabolism, n.e.c. Dosage and Administration for

Sponsors

Abbott Japan Co., Ltd.
Lead Sponsor
Eisai Co., Ltd.
Collaborator

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Inclusion criteria: - Subject was age 20 or older and in good health (Investigator discretion) with a recent stable medical history. - Subject had a clinical diagnosis of psoriasis for at least 6 months, and had moderate to severe plaque psoriasis Exclusion criteria: - Subject had previously received anti-TNF therapy. - Subject cannot discontinue systemic therapies and/or topical therapies for the treatment of psoriasis and cannot avoid UVA, UVB or PUVA phototherapy - Subject is taking or requires oral or injectible corticosteriods - Subject considered by the investigator, for any reason, to be an unsuitable candidate for the study - Female subject who is pregnant or breast-feeding or considering becoming pregnant

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Proportion of subjects with clinical response relative to Baseline PASI score—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026